Base de données sur les brevets canadiens / Sommaire du brevet 2703807 

Énoncé de désistement de responsabilité concernant l'information provenant de tiers

Une partie des informations de ce site Web à été fournie par des sources externes. Le gouvernement du Canada n'assume aucune responsabilité concernant la précision, l'actualité ou la fiabilité des informations fournies par les sources externes. Les utilisateurs qui désirent employer cette information devraient consulter directement la source des informations. Le contenu fournit par les sources externes n'est pas assujetti aux exigences sur les langues officielles, la protection des renseignements personnels et l'accessibilité.

Disponibilité de l'Abrégé et des Revendications

L'apparition de différences dans le texte et l'image des Revendications et de l'Abrégé dépend du moment auquel le document est publié. Les textes des Revendications et de l'Abrégé sont affichés :

  • lorsque la demande peut être examinée par le public;
  • lorsque le brevet est émis (délivrance).
(12) Demande de brevet: (11) CA 2703807
(54) Titre français: COMPOSITES HYDROGELS A GELIFICATION THERMIQUE INVERSEE PRESENTANT UNE STABILITE ACCRUE
(54) Titre anglais: ENHANCED STABILITY OF INVERSE THERMAL GELLING COMPOSITE HYDROGELS
(51) Classification internationale des brevets (CIB):
  • C08L 1/28 (2006.01)
  • A23L 29/20 (2016.01)
  • A61K 47/36 (2006.01)
  • A61K 47/38 (2006.01)
  • A61L 27/40 (2006.01)
  • A61L 27/52 (2006.01)
  • C08J 3/075 (2006.01)
  • C08L 5/08 (2006.01)
  • C08L 101/00 (2006.01)
(72) Inventeurs (Pays):
  • SHOICHET, MOLLY S. (Canada)
  • KANG, CATHERINE E. (Etats-Unis d'Amérique)
  • BAUMANN, M. DOUGLAS (Canada)
(73) Titulaires (Pays):
  • THE GOVERNING COUNCIL OF THE UNIVERSITY OF TORONTO (Canada)
(71) Demandeurs (Pays):
  • THE GOVERNING COUNCIL OF THE UNIVERSITY OF TORONTO (Canada)
(74) Agent: NORTON ROSE FULBRIGHT CANADA LLP/S.E.N.C.R.L., S.R.L.
(45) Délivré:
(22) Date de dépôt: 2010-05-12
(41) Mise à la disponibilité du public: 2011-11-12
Requête d’examen: 2015-05-12
(30) Licence disponible: S.O.
(30) Langue des documents déposés: Anglais

Abrégé français

La présente invention porte sur un hydrogel composite comprenant un mélange dune solution aqueuse dun polysaccharide anionique ou dun dérivé de celui-ci, comme du hyaluronane (aussi communément appelé de lacide hyaluronique) ou un dérivé de celui-ci, et dune solution de méthylcellulose ou autre dérivé de cellulose soluble dans leau de celui-ci, comportant des particules polymères dispersées, comme des particules hydrophobes polymères dans celui-ci sélectionnées à partir de microparticules et de nanoparticules, et dans lequel la stabilité de lhydrogel est améliorée par rapport à la stabilité de lhydrogel seul. Les particules polymères peuvent contenir au moins un agent thérapeutique, auquel cas chaque agent thérapeutique présente une vitesse de libération soutenue qui peut être accordée ou modifiée en sélectionnant la composition polymère appropriée de microparticules ou de nanoparticules. Le composite peut être injectable et, en labsence dun agent thérapeutique, être utilisé en tant quagent de gonflement à des fins de chirurgie reconstructrice et esthétique, ou il peut servir de plateforme pour ladministration dagents thérapeutiques.


Abrégé anglais

The present invention relates to a composite hydrogel comprising a blend of an aqueous solution of an anionic polysaccharide or a derivative thereof, such as hyaluronan (also commonly referred to as hyaluronic acid) or a derivative thereof and an aqueous solution of methylcellulose or another water soluble cellulose derivative thereof, having dispersed polymeric particles, such as polymeric hydrophobic particles therein selected from micro particles and nanoparticles, and wherein the stability of the hydrogel is enhanced relative to the stability of the hydrogel alone. The polymeric particles may contain at least one therapeutic agent, in which case each therapeutic agent exhibits a linear sustained release rate that can be tuned or altered by selecting the appropriate polymer formulation of the micro particles and/or nanoparticles. The composite may be injectable, and in the absence of a therapeutic agent may be used as a bulking agent for reconstructive and cosmetic surgery or may act as a platform for subsequent delivery of therapeutic agents.


Note : Les revendications sont présentées dans la langue officielle dans laquelle elles ont été soumises.




WHAT WE CLAIM IS

1. A hydrogel composite comprising a blend of an aqueous solution of an
anionic
polysaccharide or a derivative thereof and methylcellulose or other water
soluble hydrophobic
cellulose derivative, together with dispersed hydrophobic polymeric particles
selected from
microparticles and nanoparticles, wherein the stability of the hydrogel with
the dispersed polymeric
particles is enhanced relative to the stability of the hydrogel alone.

2. The hydrogel composite as claimed in claim 1 wherein the composite is used
as a bulking
agent for cosmetic surgery, reconstructive surgery and in foods.

3. The hydrogel composite as claimed in claim 1 wherein some or all of the
dispersed
hydrophobic polymer particles are encapsulated microparticles or nanoparticles
that comprise at
least one therapeutic agent and each of the at least one therapeutic agents
has a sustained release
profile.

4. The hydrogel composite as claimed in claim 3 wherein some or all of the
dispersed
hydrophobic polymer particles are encapsulated microparticles or nanoparticles
that comprise at
least one therapeutic agent and each of the at least one therapeutic agents
has a linear sustained
release profile.

5. The hydrogel composite as claimed in claim 1 wherein the composite
comprises hyaluronan
or a derivative thereof and methyl cellulose or other water soluble
hydrophobic cellulose derivative.
6. The hydrogel composite as claimed in claim 3 wherein the composite
comprises hyaluronan
or a derivative thereof and methyl cellulose or other water soluble
hydrophobic cellulose derivative.
7. The hydrogel composite as claimed in claim 1, wherein the anionic
polysaccharide or a
derivative thereof comprises from about 100 to about 7,000 kg/mol and the
methylcellulose or other
water soluble hydrophobic cellulose derivative comprises from about 2 to about
3,000 kg/mol.
8. The hydrogel composite as claimed in claim 5, wherein the hyaluronan or a
derivative
thereof comprises from about 100 to about 7,000 kg/mol and the methylcellulose
or other water
soluble hydrophobic cellulose derivative comprises from about 2 to about 3,000
kg/mol.





9. The hydrogel composite as claimed in claim 1, wherein the ratio of anionic
polysaccharide or
a derivative thereof to the methylcellulose or other water soluble hydrophobic
cellulose derivative
comprises from about 1:20 to about 1:1 w/w.

10. The hydrogel composite as claimed in claim 5, wherein the ratio of
hyaluronan or a
derivative thereof to the methylcellulose or other water soluble hydrophobic
cellulose derivative
comprises from about 1:20 to about 1:1 w/w.

11. The hydrogel composite as claimed in claim 1, wherein the amount of
anionic
polysaccharide or a derivative thereof comprises from about 0.5% to about 5.0%
by weight and the
methylcellulose or other water soluble hydrophobic cellulose derivative
comprises from about 1.0%
to about 10% by weight of the composite.

12. The hydrogel composite as claimed in claim 5, wherein the amount of
hyaluronan or a
derivative thereof comprises from about 0.5% to about 5.0% by weight and the
methylcellulose or
other water soluble hydrophobic cellulose derivative comprises from about 1.0%
to about 10% by
weight of the composite.

13. The hydrogel composite as claimed in claim 1, wherein the polymeric
particles are
hydrophobic polymer particles selected from degradable polymers selected from
the group (but not
limited to this group) consisting of aliphatic polyesters, polydioxanones,
polyhydroxyalkanoate,
polyanhydrides, aliphatic-aromatic polyesters, aliphatic polyamides, amide
ester copolymers,
urethane ester copolymers, urethane amide copolymers and urea ester
copolymers; and from non-
degradable polymers selected from the group consisting of polyacrylates;
ethylene-vinyl acetates;
acyl substituted cellulose acetates; non-degradable polyurethanes;
polystyrenes; polyvinyl chlorides;
polyvinyl fluorides; poly(vinyl imidazoles); .
polyolefins; polyethylene oxides;
starches; or blends or copolymers thereof.
14. The hydrogel composite as claimed in claim 1, wherein the dispersed
hydrophobic polymeric
particle load comprises from about 1 to about 20 wt%, based on the composite.

15. The hydrogel composite as claimed in claim 3, wherein the dispersed
polymeric particle load
comprises from about 1 to about 20 wt%, based on the composite.

41


16. The hydrogel composite as claimed in claim 1, wherein the dispersed
polymeric particles are
selected from particle sizes of from about 50 nm to about 40 µm.


17. The hydrogel composite as claimed in claim 3, wherein the dispersed
polymeric particles are
selected from particle sizes of from about 220 nm to about 37 µm.


18. The hydrogel composite as claimed in claim 3, wherein the delivered
therapeutic agent load
from the encapsulated particles is in the range of from about 0.1 to about 30
wt% (drug mass as a
percentage of the drug loaded particle mass).


19. The hydrogel composite as claimed in claim 1, wherein the aqueous solution
is selected from
the group comprising water, saline, artificial cerebrospinal fluid, and
buffered solutions.


20. The hydrogel composite as claimed in claim 5 having an altered chemical
functionality by
the addition of at least one functional group to the hyaluronan or the
derivative thereof or the
methylcellulose or other water soluble hydrophobic cellulose derivative
selected from the group
consisting of carboxylic acid, primary amine, aldehyde, hydrazide, maleimide,
thiol, furan, alkyne,
azide, alkene, urethane, and primary alcohol.


21. The hydrogel composite as claimed in claim 5 wherein the therapeutic agent
is selected from
the group comprising anaesthetics for use in caudal, epidural, inhalation,
injectable, retrobulbar, and
spinal applications; analgesics, selected from the group comprising
acetaminophen, ibuprofen,
fluriprofen, ketoprofen, voltaren, phenacetin and salicylamide; anti-
inflammatories selected from the
group comprising naproxen and indomethacin; antihistamines, selected from the
group comprising
chlorpheniramine maleate, phenindamine tartrate, pyrilamine maleate,
doxylamine succinate,
henyltoloxamine citrate, diphenhydramine hydrochloride, promethazine,
brompheniramine maleate,
dexbrompheniramine maleate, clemastine fumarate and triprolidine; antitussives
selected from the
group comprising dextromethorphan hydrobromide and guaifenesin; expectorants;
decongestants,
selected from the group comprising phenylephrine hydrochloride,
phenylpropanolamine
hydrochloride, pseudoephedrine hydrochloride, and ephedrine; antibiotics
selected from the group
comprising amebicides, broad and medium spectrum, fungal medications,
monobactams and viral
agents; bronchodilators selected from the group comprising theophylline,
albuterol and terbutaline;
cardiovascular preparations selected from the group comprising diltiazem,
propranolol, nifedepine,


42


clonidine, alpha adrenoceptor agonists, alpha receptor blocking agents, alpha
and beta receptor
blocking agents, antiotensin converting enzyme inhibitors, beta blocking
agents, calcium channel
blockers, and cardiac glycosides; central nervous system drugs selected from
the group comprising
thioridazine, diazepam, meclizine, ergoloid mesylates, chlorpromazine,
carbidopa and levodopa;
metal salts selected from the group comprising potassium chloride and lithium
carbonate; minerals
selected from the group consisting of iron, chromium, molybdenum and
potassium;
immunomodulators; immunosuppressives selected from the group comprising
minocycline,
cyclosporine A; thyroid preparations selected from the group comprising
synthetic thyroid hormone,
and thyroxine sodium; peptide and glycoprotein hormones and analogues selected
from the group
comprising human chorionic gonadotrophin (HCG), corticotrophin, human growth
hormone (HGH--
Somatotrophin) and erythropoietin (EPO); steroids and hormones selected from
the group
comprising ACTH, anabolics, androgen and estrogen combinations, androgens,
corticoids and
analgesics, estrogens, glucocorticoid, gonadotropin, gonadotropin releasing,
hypocalcemic,
menotropins, parathyroid, progesterone, progestogen, progestogen and estrogen
combinations,
somatostatin-like compounds, urofollitropin, vasopressin, methyl prednisolone,
GM1 ganglioside,
cAMP, and others; vitamins selected from the group comprising water-soluble
vitamins and
veterinary formulations; growth factors selected from the group comprising
EGF, FGF2 and
neurotrophin; peptides, peptide mimetics and other protein preparations; DNA;
and, small
interfering RNAs; with or without a pharmaceutically acceptable carrier or
preservative.


22. The hydrogel composite as claimed in claim 5 having an altered rate of
degradation by cross-
linking the hyaluronan or the derivative thereof or by increasing the
hydrophobicity of the
hyaluronan or the derivative thereof.


23. The hydrogel composite as claimed in claim 5 wherein the therapeutic agent
is encapsulated
in a microsphere, nanoparticle or liposome.


24. The hydrogel composite as claimed in claim 5 wherein a charge stabilizer
is added to
promote an interaction between the blend and the therapeutic agent or the
therapeutic agent is
covalently bonded to the hyaluronan or the derivative thereof.


25. The hydrogel composite as claimed in claim 5 wherein the other hydrophobic
water soluble
cellulose derivatives are selected from the group comprising hydroxypropyl
methylcellulose,


43


ethylcellulose, 3-O-ethylcellulose, hydroxypropyl methylcellulose phthalate,
hydrophobically
modified hydroxyethyl cellulose selected from ethyl(hydroxyethyl)cellulose, 6-
O-alkylated
cellulose, cellulose octanoate sulfate, cellulose lauroate sulfate, cellulose
stearoate sulfate, and
cationic derivatives thereof, 6-O-benzylcellulose, 2,3-di-O-methyl-6-O-
benzylcellulose, 2,3-di-O-
benzylcellulose, 2,3-di-O-benzyl-6-O-methylcellulose, 2,3,6-tri-O-
benzylcellulose, hydroxypropyl
methylcellulose acetate succinate, O-2-[2-(2-methoxyethoxy)ethoxy]acetyl
cellulose.


26. The hydrogel composite as claimed in claim 5 wherein the derivatives of
hyaluronan are
esters of hyaluronan resulting from esterification with different classes of
alcohols such as aliphatic,
cycloaliphatic and heterocyclic.


27. A method for manufacturing a hydrogel composite as claimed in claim 1
which comprises
the steps of 1) providing an aqueous solution of methylcellulose or other
cellulose derivative; 2)
mixing hyaluronan or a derivative thereof into the aqueous solution; 3)
dispersing hydrophobic
polymeric particles selected from micro particles and nanoparticles into the
aqueous solution to form
a stable hydrogel composite that has enhanced stability relative to a hydrogel
without the dispersed
particles.


28. A method for manufacturing a hydrogel composite as claimed in claim 5 for
sustained
release delivery of at least one therapeutic agent which comprises the steps
of 1) providing an
aqueous solution of methylcellulose or other cellulose derivative; 2) mixing
hyaluronan or a
derivative thereof into the aqueous solution; 3) dispersing polymeric
particles selected from micro
particles and nanoparticles into the aqueous solution to form a stable
hydrogel composite that has
enhanced stability relative to a hydrogel without the dispersed particles, the
dispersed hydrophobic
polymer particles comprising encapsulated micro particles or nanoparticles
that comprise at least
one therapeutic agent and each of the at least one therapeutic agents has its
own linear sustained
release profile.


29. A method for the treatment of central nervous system injury selected from
spinal cord injury,
stroke, and traumatic brain injury comprising delivering into the intrathecal
or sub-dural space, a
hydrogel composite comprising hyaluronan or a derivative thereof and
methylcellulose or other
water soluble cellulose derivative, and at least one therapeutic agent
encapsulated in microparticles
and nanoparticles dispersed in the hydrogel composite to provide a sustained
release profile of the at


44


least one therapeutic agent to the injured spinal cord to promote endothelial
cell proliferation and
blood vessel formation.


30. A method as claimed in claim 29 for the treatment of spinal cord injury
comprising
delivering into an intrathecal space, a hydrogel composite comprising an
anionic polysaccharide or a
derivative thereof and methylcellulose or other water soluble cellulose
derivative, and at least one
therapeutic agent selected from FGF2, FGF1, vascular endothelial growth factor
(VEGF), platelet
derived growth factor (PDGF), angiopoietin 1, and angiopoietin 2 dispersed in
the hydrogel
composite as encapsulated microparticles and nanoparticles to provide a
sustained release profile of
the at least one therapeutic agent to the injured spinal cord to promote
endothelial cell proliferation
and blood vessel formation.




Désolé, le dessin représentatatif concernant le document de brevet no 2703807 est introuvable.

Pour une meilleure compréhension de l’état de la demande ou brevet qui figure sur cette page, la rubrique Mise en garde , et les descriptions de Brevet , États administratifs , Taxes périodiques et Historique des paiements devraient être consultées.

États admin

Titre Date
(22) Dépôt 2010-05-12
(41) Mise à la disponibilité du public 2011-11-12
Requête d'examen 2015-05-12

Taxes périodiques

Description Date Montant
Dernier paiement 2017-04-06 100,00 $
Prochain paiement si taxe applicable aux petites entités 2018-05-14 100,00 $
Prochain paiement si taxe générale 2018-05-14 200,00 $

Avis : Si le paiement en totalité n’a pas été reçu au plus tard à la date indiquée, une taxe supplémentaire peut être imposée, soit une des taxes suivantes :

  • taxe de rétablissement prévue à l’article 7 de l’annexe II des Règles sur les brevets ;
  • taxe pour paiement en souffrance prévue à l’article 22.1 de l’annexe II des Règles sur les brevets ; ou
  • surtaxe pour paiement en souffrance prévue aux articles 31 et 32 de l’annexe II des Règles sur les brevets.

Historique des paiements

Type de taxes Anniversaire Échéance Montant payé Date payée
Dépôt 200,00 $ 2010-05-12
Taxe périodique - Demande - nouvelle loi 2 2012-05-14 50,00 $ 2012-02-21
Taxe périodique - Demande - nouvelle loi 3 2013-05-13 50,00 $ 2013-03-20
Taxe périodique - Demande - nouvelle loi 4 2014-05-12 50,00 $ 2014-04-17
Taxe périodique - Demande - nouvelle loi 5 2015-05-12 100,00 $ 2015-04-24
Requête d'examen 400,00 $ 2015-05-12
Taxe périodique - Demande - nouvelle loi 6 2016-05-12 100,00 $ 2016-05-10
Taxe périodique - Demande - nouvelle loi 7 2017-05-12 100,00 $ 2017-04-06
Final 150,00 $ 2017-09-06

Pour visionner les fichiers sélectionnés, entrer le code reCAPTCHA :



  • Pour visualiser une image, cliquer sur un lien dans la colonne description du document. Pour télécharger l'image (les images), cliquer l'une ou plusieurs cases à cocher dans la première colonne et ensuite cliquer sur le bouton "Télécharger sélection en format PDF (archive Zip)".
  • Liste des documents de brevet publiés et non publiés sur la BDBC.
  • Si vous avez des difficultés à accéder au contenu, veuillez communiquer avec le Centre de services à la clientèle au 1-866-997-1936, ou envoyer un courriel au Centre de service à la clientèle de l'OPIC.

Filtre Télécharger sélection en format PDF (archive Zip)
Description du
Document
Date
(yyyy-mm-dd)
Nombre de pages Taille de l’image (Ko)
Abrégé 2010-05-12 1 26
Description 2010-05-12 39 2 407
Revendications 2010-05-12 6 304
Page couverture 2011-10-28 1 41
Dessins 2010-05-12 8 151
Description 2010-05-13 39 2 413
Description 2016-10-17 40 2 450
Revendications 2016-10-17 4 216
Description 2017-01-06 40 2 445
Correspondance 2011-08-12 4 124
Correspondance 2010-06-11 1 18
Poursuite-Amendment 2010-05-13 3 131
Poursuite-Amendment 2015-05-12 2 73
Poursuite-Amendment 2016-04-18 4 268
Poursuite-Amendment 2016-10-17 11 556
Poursuite-Amendment 2016-12-12 3 167
Poursuite-Amendment 2017-01-06 3 121
Correspondance 2017-09-06 2 69
Page couverture 2017-09-22 1 41